Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb 20;23(1):100.
doi: 10.1186/s12879-023-08050-0.

Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010-2018)

Samuel Bourassa-Blanchette  1   2 , Marit M Biesheuvel  3 , John C Lam  4 , Alexander Kipp  5   6 , Deirdre Church  7   5   6 , Julie Carson  5   6 , Bruce Dalton  8 , Michael D Parkins  7 , Herman W Barkema  3 , Daniel B Gregson  7   5   6
Affiliations

Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010-2018)

Samuel Bourassa-Blanchette et al. BMC Infect Dis. .

Abstract

Background: Candidemia is increasing in frequency and is associated with high mortality. We sought to determine the burden of illness, the population it affects and its resistance profile in our region.

Methods: The Calgary Zone (CZ) provides all care for residents of Calgary and surrounding communities (~ 1.69 million) via five tertiary hospitals each served by a common single laboratory for acute care microbiology. All adult patients in the CZ with at least one Candida spp.-positive blood culture between January 1, 2010, and December 31, 2018, were identified using microbiological data from Calgary Lab Services, the laboratory that processes > 95% of all blood culture samples in the CZ, were reviewed for the study.

Results: The overall annual incidence of candidemia among individuals living in the CZ was 3.8 per 100,000 persons (Median age 61 years (IQR 48-72) and 221/455 (47.4%) were female). C. albicans was the most common species (50.6%), followed by C. glabrata, (24.0%). No other species accounted for more than 7% of cases. Overall mortality at 30, 90, and 365 days was 32.2, 40.1, and 48.1% respectively. Mortality rate did not differ by Candida species. Of individuals who developed candidemia, more than 50% died within the next year. No new resistance pattern has emerged in the most common Candida species in Calgary, Alberta.

Conclusions: In Calgary, Alberta, the incidence of candidemia has not increased in the last decade. C. albicans was the most common species and it remains susceptible to fluconazole.

Keywords: Antifungal susceptibility; Candida; Fungemia; Incidence; Mortality.

PubMed Disclaimer

Conflict of interest statement

The authors confirm there are no competing interest.

Figures

Fig. 1
Fig. 1
Overall annual incidence of candidemia per 100,000 citizens among individuals in the Calgary Health Region, and the annual incidence per 100,000 citizens among individuals 0–39 years, 40–59 years, 60–79 years and > 80 years between 2010 and 2018
Fig. 2
Fig. 2
Distribution of species causing candidemia between 2010 and 2018
Fig. 3
Fig. 3
Relative proportion with 95% confidence intervals of Candida species causing Candida bloodstream infection each year, over time between 2010 and 2018
Fig. 4
Fig. 4
Length in days between first positive and first negative culture for 343 patients with documented clearance of Candida spp. from blood
See this image and copyright information in PMC

References

    1. Zaoutis TE, Argon J, Chu J, Berlin JA, Walsh TJ, Feudtner C. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis. 2005;41:1232–1239. doi: 10.1086/496922. - DOI - PubMed
    1. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surv. J Clin Microbiol. 2001;39:3254–3259. doi: 10.1128/JCM.39.9.3254-3259.2001. - DOI - PMC - PubMed
    1. Tsay SV, Mu Y, Williams S, Epson E, Nadle J, Bamberg WM, et al. Burden of Candidemia in the United States, 2017. Clin Infect Dis. 2020;e449–e453. - PubMed
    1. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother. 2005;56:532–537. doi: 10.1093/jac/dki258. - DOI - PubMed
    1. Corzo-Leon DE, Alvarado-Matute T, Colombo AL, Cornejo-Juarez P, Cortes J, Echevarria JI, et al. Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals. PLoS ONE. 2014;9:e97325. doi: 10.1371/journal.pone.0097325. - DOI - PMC - PubMed